Eyenovia

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Eyenovia anticipates FDA approval for MydCombi, focusing on growth

Eyenovia's Q4 2022 call highlighted financial results, key milestones, and upcoming FDA approval for MydCombi. The company's focus on product candidates and strategic partnerships positions it for growth.

Eyenovia reports FDA approval for MydCombi, eyes ophthalmology market growth

Eyenovia's Q1 2023 performance reflects financial discipline and strategic progress in product development and partnerships, positioning the company for future growth.
The company's focus on efficiency, market potential in ophthalmology, and innovative products like Optejet present opportunities for expansion and value creation.
Challenges lie in raising awareness about new products, balancing financial discipline with growth ambitions, and successfully executing product launches in competitive markets.

Eyenovia reports Q2 loss but hits milestones, eyes growth opportunities

Eyenovia's Q2 2023 performance reflects a net loss but highlights successful commercial milestones for Mydcombi and progress on Apersure.
The company's strengths lie in innovation with Optejet technology, expanding manufacturing capabilities, and promising licensing agreements.
Challenges include managing losses, finalizing partnerships, and meeting regulatory timelines, while opportunities exist in partnerships, market expansion, and revenue growth.
Overall, Eyenovia's strategic focus on product development, partnerships, and financial management positions it for future growth and success in the pharmaceutical industry.

Eyenovia reports Q3 losses, eyes FDA approvals and strategic partnerships

Eyenovia's Q3 performance reflects strategic investments in product development and partnerships to drive future growth. The company's focus on innovative products like Mydcombi and APP13007 positions them well for market expansion. While facing financial challenges and regulatory risks, Eyenovia's strong leadership and partnership progress indicate a promising outlook for the future.

Eyenovia reports Q4 progress with FDA approvals and revenue strategies

Eyenovia's Q4 2023 earnings call highlighted progress in product development, manufacturing capabilities, and revenue potential.
The company's focus on innovation, competitive pricing, and strategic partnerships positions it for future growth and market success.
Challenges include market competition, operational expenses, and the need for promotional efforts to drive product adoption.
Opportunities lie in collaborations, product launches, and strategic initiatives to enhance market presence and drive revenue growth.

Eyenovia reports Q1 loss but eyes revenue growth opportunities

Eyenovia's Q1 2024 performance reflects a focus on commercialization, pipeline advancement, and strategic collaborations amidst a net loss and increased expenses.
With a strong product portfolio, differentiated offerings, and key partnerships, Eyenovia is well-positioned to capitalize on revenue opportunities in the eye care market.
While facing challenges in managing costs and securing capital, Eyenovia has opportunities to drive growth through product launches, market expansion, and regulatory milestones.

Eyenovia reports Q2 loss but sees growth potential in innovations

Eyenovia's Q2 2024 performance reflects strategic investments in product development and partnerships, with a focus on innovative technologies like Optejet.
While facing financial challenges from increased expenses, Eyenovia's revenue potential from licensing agreements and product pipeline remains strong.
The company's opportunities lie in capitalizing on Optejet advancements, expanding market reach through collaborations, and navigating regulatory milestones for key products.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arctic Vision also licensed and is developing Eyenovia's programs for pediatric progressive myopia (MicroPine) and pharmacologic mydriasis (MydCombi™) in Greater China and South Korea Arctic Vision also licensed and is developing Eyenovia's programs for pediatric progressive myopia (MicroPine) and pharmacologic mydriasis (MydCombi™) in Greater China and South Korea

Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational products, today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be held virtually via live webcast on Thursday, June 16, 2022 at 10:00 am EDT. Stockholders of record as of the close of business on April 18, 2022, are entitled to vote at the Annual Meeting.

UPDATE: Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders

Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders

CEO Dr. Sean Ianchulev will transition to non-executive Chairman of the Board CEO Dr. Sean Ianchulev will transition to non-executive Chairman of the Board

Eyenovia Announces Planned Chief Executive Officer Transition

Eyenovia, Inc. (NASDAQ:EYEN ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Eric Ribner - Investor Relations Sean Ianchulev - President, Chief Executive Officer & Chief Medical Officer Michael Rowe - Chief Operating Officer John Gandolfo - Chief Financial Officer Conference Call Participants Tim Chiang - Northland Capital Operator Thank you for standing by, and welcome to the Eyenovia First Quarter 2022 Earnings Call. During the presentation, all participants will be in a listen only mode.

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q1 2022 Results - Earnings Call Transcript

Mydcombi™ NDA resubmission on track for Q3 2022

Eyenovia Reports First Quarter 2022 Financial Results

Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day

Eyenovia to Report First Quarter 2022 Results on Thursday, May 12

Presentation to review historic issues related to glaucoma therapies and how these may be addressed through the use of Optejet® technology Presentation to review historic issues related to glaucoma therapies and how these may be addressed through the use of Optejet® technology

Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

Results of “SPEED” study confirm the speed of diagnostic effectiveness of a single microdose array print (MAP™) spray using the company's proprietary OpteJet® dispenser Results of “SPEED” study confirm the speed of diagnostic effectiveness of a single microdose array print (MAP™) spray using the company's proprietary OpteJet® dispenser

Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2021 Results - Earnings Call Transcript

Successfully completed Type A meeting with FDA and anticipates MydCombi™ NDA resubmission in Q3 2022

Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results

Eyenovia to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28

Study conducted with Tufts Medical Center represents a breakthrough showing that Microdose Array Print (MAP™) technology can provide similar benefits of non-preserved medications Study conducted with Tufts Medical Center represents a breakthrough showing that Microdose Array Print (MAP™) technology can provide similar benefits of non-preserved medications

Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company has entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd., a leading health care investor, in an offering of 3,000,000 shares of its common stock pre-funded warrants to purchase up to 1,870,130 shares of its common stock, and common warrants to purchase up to 4,870,130 shares of its common stock (the "Offering"). The shares of common stock and the pre-funded warrants are each being sold in combination with corresponding common warrants. The aggregate offering price for each share of common stock or each pre-funded warrant and, in each case, the accompanying common warrant is $3.08, which was the market price of the common stock as of the close of trading on March 3, 2022.

Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master Fund Ltd.

I will share a status report on events since my original article. I will give my readers a rationale of what happened to cause the CRL delay with the FDA decision. New information and an updated timeline will be shared.

Eyenovia: I Can See You Better - Now

loanDepot

MannKind

Oncternal Therapeutics Inc

Performant Financial

P3 Health Partners Inc

Pixelworks

Vaccinex Inc

Penny stocks to buy now according to insiders. The post 8 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

8 Penny Stocks To Buy Now According To Insiders In 2022

No additional clinical work required; NDA resubmission anticipated in Q3 2022 No additional clinical work required; NDA resubmission anticipated in Q3 2022

Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission

NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced changes to its Board of Directors.

Eyenovia Announces Changes to Board of Directors

Eyenovia, Inc.'s (EYEN) CEO Dr. Sean Ianchulev on Q3 2021 Results - Earnings Call Transcript

Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of 11.54% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates

On track with VISION-2 phase 3 presbyopia trial and expedited resubmission of MydCombi™ New Drug Application as a drug/device combination in early 2022

Eyenovia Reports Third Quarter 2021 Financial Results

Eyenovia is an under-the-radar ophthalmic company with a large addressable market and big opportunities ahead just received a Complete Response Letter (CRL) from the FDA for its leading drug candidate.

Eyenovia: FDA Setback Is Big Opportunity For Investors

Discussion to Include Future Potential Treatment Options, Including MicroPine (atropine ophthalmic spray), for reduction of myopia progression in pediatrics Discussion to Include Future Potential Treatment Options, Including MicroPine (atropine ophthalmic spray), for reduction of myopia progression in pediatrics

Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting

Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be released on Thursday, November 11, after the close.

CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10

Company to host an investor conference call and webcast at 5:00pm ET on that day Company to host an investor conference call and webcast at 5:00pm ET on that day

News for Eyenovia Stock (EYEN)